Celldex Therapeutics

Celldex Therapeutics CLDX Stock

$29.25   0.966519%
Add to favorites
Market Cap
$2.30B
LOW - HIGH [24H]
$28.20 - $29.38
VOLUME [24H]
$879.73K
P/E Ratio
0
Earnings per share
-$4.35
ISIN
US15117B2025
Price   Prediction

Celldex Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Celldex Therapeutics CLDX Financial and Trading Overview

Celldex Therapeutics stock price 29.25 USD
Previous Close 28.97 USD
Open 28.95 USD
Bid 24.69 USD x 100
Ask 32.94 USD x 100
Day's Range 28.2 - 29.13 USD
52 Week Range 22.1 - 45.14 USD
Volume 342.23K USD
Avg. Volume 1.36M USD
Market Cap 2.28B USD
Beta (5Y Monthly) 0.896
PE Ratio (TTM) N/A
EPS (TTM) -4.35 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 63.07 USD

CLDX Valuation Measures

Enterprise Value 1.56B USD
Trailing P/E N/A
Forward P/E -6.8272076
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 14423.589
Price/Book (mrq) 3.1879601
Enterprise Value/Revenue 9888.086
Enterprise Value/EBITDA -4.845

Trading Information

Celldex Therapeutics Stock Price History

Beta (5Y Monthly) 0.896
52-Week Change 8.42%
S&P500 52-Week Change 12.83%
52 Week High 45.14 USD
52 Week Low 22.1 USD
50-Day Moving Average 35.48 USD
200-Day Moving Average 32.56 USD

CLDX Share Statistics

Avg. Volume (3 month) 1.36M USD
Avg. Daily Volume (10-Days) 1.15M USD
Shares Outstanding 78.53M
Float 73.02M
Short Ratio 6
% Held by Insiders 0.27%
% Held by Institutions 109.90%
Shares Short 11.01M
Short % of Float 16.62%
Short % of Shares Outstanding 14.01%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:15

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -366468.19%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -27.61%
Return on Equity (ttm) -43.87%

Income Statement

Revenue (ttm) 158K USD
Revenue Per Share (ttm) 0.002 USD
Quarterly Revenue Growth (yoy) -97.00000000000000000000000000000000%
Gross Profit (ttm) -278648992 USD
EBITDA -322432000 USD
Net Income Avi to Common (ttm) -300548992 USD
Diluted EPS (ttm) -4.35
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 717.59M USD
Total Cash Per Share (mrq) 9.14 USD
Total Debt (mrq) 4.9M USD
Total Debt/Equity (mrq) 0.69 USD
Current Ratio (mrq) 11.821
Book Value Per Share (mrq) 9.103

Cash Flow Statement

Operating Cash Flow (ttm) -235566000 USD
Levered Free Cash Flow (ttm) -133080496 USD

Profile of Celldex Therapeutics

Country United States
State NJ
City Hampton
Address Perryville III Building
ZIP 08827
Phone 908 200 7500
Website https://www.celldex.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 198

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Q&A For Celldex Therapeutics Stock

What is a current CLDX stock price?

Celldex Therapeutics CLDX stock price today per share is 29.25 USD.

How to purchase Celldex Therapeutics stock?

You can buy CLDX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Celldex Therapeutics?

The stock symbol or ticker of Celldex Therapeutics is CLDX.

Which industry does the Celldex Therapeutics company belong to?

The Celldex Therapeutics industry is Biotechnology.

How many shares does Celldex Therapeutics have in circulation?

The max supply of Celldex Therapeutics shares is 78.53M.

What is Celldex Therapeutics Price to Earnings Ratio (PE Ratio)?

Celldex Therapeutics PE Ratio is now.

What was Celldex Therapeutics earnings per share over the trailing 12 months (TTM)?

Celldex Therapeutics EPS is -4.35 USD over the trailing 12 months.

Which sector does the Celldex Therapeutics company belong to?

The Celldex Therapeutics sector is Healthcare.

Celldex Therapeutics CLDX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 25955.34 USD —
-0.21
5.73B USD — 25866.15 USD — 26111.62 USD — — 5.73B USD —
us US Tech Biotechnology Total Retu XNBI US 7640.15 USD —
-1.13
— — 7582.06 USD — 7679.98 USD — — — —
us US Tech Capital Market Composite RCMP US 115.14 USD —
-1.35
— — 115.06 USD — 116.22 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3770.94 USD —
-0.28
— — 3736.98 USD — 3784.46 USD — — — —
us US Tech Health Care IXHC US 1327.92 USD —
-0.97
— — 1320.94 USD — 1335.06 USD — — — —
us US Tech Composite Total Return XCMP US 32064.01 USD —
-0.21
— — 31953.83 USD — 32257.07 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 3009.36 USD —
-0.47
— — 2982.52 USD — 3012.47 USD — — — —
$2.73T
Total marketcap
$65.05B
Total volume
BTC 59.46%   •   ETH 10.64%
Dominance
Select currency